Наукові праці. Кафедра онкології та радіології з радіаційною медициною
Постійне посилання зібрання
Переглянути
Перегляд Наукові праці. Кафедра онкології та радіології з радіаційною медициною за Ключові слова "618.19-006-085"
Зараз показуємо 1 - 1 з 1
Результатів на сторінці
Налаштування сортування
Документ Option therapeutic approach for primary breast cancer(Colloguium-journal Warszawa, Polska, 2020-10) Zhukova, T. O.; Vasko, L. N.; Nestulia, K. I.; Aikian, A. Z.; Mukovoz, O. E.; Жукова, Тетяна Олександрівна; Васько, Лариса Миколаївна; Нестуля, Катерина Ігорівна; Айкян, Артем Завенович; Муковоз, Оксана Євгенівна; Жукова, Татьяна Александровна; Васько, Лариса Николаевна; Нестуля, Катерина Игоревна; Айкян, Артем Завенович; Муковоз, Оксана ЕвгеньевнаAbstract. The first place in the ranking of oncology and the most acute oncology problem is breast cancer (BC), in the vast majority of women [1,2,3,5,18]. The rate of abstinence is high, and the percentage of patients receiving special therapy is 80.4%. All this indicates a low level of qualified care (Kolesnik O.O., Fedorenko Z.P., 2017). The aim of the study was the desire to study the effectiveness of various schemes of preoperative chemo-radiation therapy with radioimodification in the scheme of complex treatment of primary localized BC. Research results and their discussion. Analyzing 1 year of supervision, it is evident that 35 (83.3%) patients died in the I group, 7 died (16.7%). Patients who did not have a recurrence of the process at 1 year of life 25 (59.92%). In the II group, they died at 1 year - 6 (12.76%), and patients without relapsing 36 (76.59%). Comparing the result clearly that the overall survival of a reliable result was not low, and the rate of recurrence is likely to speak for the benefit of Group II. During second year , another 14 patients died in Group І against 7 group II. In the I survived, 21 (50,0%) were left, of which 17 (40,47%) without relapse were against 34 (72,34%) of the live ones, of which 20 (42,55%) without relapse. Summing up our research, supervision over the results of treatment in two groups, we can say that the remote survival results show the following: For 36 months. The observation formed the number of patients who clearly showed the results of treatment in groups I and II. In group І, overall survival rate was 11 (26,19%), with relapse 4 (9,52%). In the II group, the total number of patients with 3 years of observation was 25 (53,19%), with relapse of 17 (36,17%). Conclusions. The study of the effectiveness of the scheme of neoadjuvant chemo-therapy in combination with radiotherapy and radiomodification (group II) showed a positive trend in survival and relapse rates as well as a satisfactory state in the manifestations of toxicity of HT and radiation manifestations compared with the proposed scheme for group I.